低氧暴露诱导肌萎缩发生的机制探讨

高海拔地区常伴随着诸多不利环境因素,使初上高原者处于应激状态,对机体代谢系统产生一系列不良影响,其中之一就是诱发骨骼肌萎缩。肌萎缩是一种肌肉功能减退的反应,表现为肌纤维横截面积减小,肌纤维类型转变和肌肉力量、耐力下降。高原环境造成的肌萎缩与低氧环境密切相关。高原训练是竞技体育中一种提高氧运输能力、心脏供血能力及最大摄氧量的有效训练方式,但此过程中造成的骨骼肌质量丢失会影响运动员力量和耐力的发挥,不利于运动表现;同时,随着高原旅游和低氧减肥的兴起,世居平原大众进入高原后发生的肌量丢失和肌力下降也会影响其健康状态。低氧暴露所诱发的肌萎缩程度由低氧浓度和暴露时长所决定,是一个多器官、多组织参与的整体调控骨骼肌蛋白代谢失衡的过程,且在不同类型的肌纤维中表现不同。但目前关于低氧暴露导致肌萎缩的机制还不完全清楚。因此,本文将就该问题相关研究进展进行综述,以期进一步阐明低氧诱导肌萎缩的生物学机制,从而利用低氧刺激更好地提高运动成绩和服务大众健康。     

白藜芦醇通过调控HIF-1α/NOX4/ROS通路抑制低氧诱导的大鼠肺动脉平滑肌细胞氧化应激与增殖

本文旨在明确白藜芦醇对低氧诱导的肺动脉平滑肌细胞(pulmonary artery smooth muscle cells, PASMCs)氧化应激与增殖的作用及分子机制。体外分离培养原代大鼠PASMCs,采用不同浓度的白藜芦醇(10、20和40μmol/L)或NADPH氧化酶(NADPH oxidases, NOXs)抑制剂VAS2870 (10μmol/L)预处理0.5 h,然后将细胞置于常氧(21%O_2, 5%CO_2)或低氧(2%O_2, 5%CO_2)中培养24h。采用CCK-8法和增殖细胞核抗原(proliferatingcellnuclearantigen,PCNA)的表达水平检测细胞增殖,用DCFH-DA测定细胞内活性氧(reactive oxygen species, ROS)的生成,用real-time RT-PCR和Western blot检测NOX1、NOX4和低氧诱导因子-1α(hypoxia inducible factor 1α, HIF-1α)的表达水平,通过小干扰RNAs (small interference RNAs, siRNAs)特异性沉默Hif-1α和Nox4后确定相关信号通路。结果显示,白藜芦醇和VAS2870均能显著抑制低氧诱导的大鼠PASMCs细胞增殖和ROS生成,同时白藜芦醇还能有效阻止低氧诱导的HIF-1α蛋白的聚集和NOX4的表达上调,而对NOX1没有明显的影响。沉默Hif-1α或Nox4后,低氧诱导的大鼠PASMCs细胞增殖和ROS累积均显著降低,且能被白藜芦醇进一步抑制。上述结果提示,白藜芦醇可能通过阻断HIF-1α/NOX4/ROS信号通路抑制低氧诱导的大鼠PASMCs氧化应激和增殖。     

低氧诱导因子-1的结构、功能、调节及其与低氧信号转导的关系

在许多类型细胞均发现低氧可诱导低氧诱导因子-1（HIF-1）水平的 增高,说明存在一个普遍的氧感受和低氧信号转导机制,其中HIF-1起着重要的作用。本文 综述了HIF-1的结构、功能和活性调节及其与低氧信号转导的关系等方面的研究进展。     

低氧影响蛋白质合成和分解的平衡诱导骨骼肌萎缩

暴露在低氧环境下,可能会引起胃肠功能障碍和摄食量下降,打破骨骼肌蛋白质合成和分解平衡,造成骨骼肌萎缩。为探讨低氧环境下骨骼肌的萎缩是低氧环境引起的还是低氧诱发的摄食量减少所致,本研究检测大鼠腓肠肌中低氧时蛋白质合成与分解相关基因的蛋白质表达。将21只雄性SD大鼠,随机分为3组：常氧对照组、低氧组（氧浓度为12.4%,模拟海拔4 000 m高度）和配对组（大鼠的摄食量与低氧组前1 d的摄食量相同）,每组7只,每天记录大鼠体重和摄食量。4周后,HE染色法观察腓肠肌肌纤维形态,Western印迹测试相关蛋白质水平。低氧组和配对组摄食量在低氧干预初期,较常氧对照组有显著性下降(P<0.05),干预后期差异不明显;干预期间,低氧组大鼠体重平均增加量(102.10 g)、体重(341.20 ± 16.75 g)、肌肉总量（226.83 ± 8.33 g）和腓肠肌肌纤维横截面积(12.67 ± 1.83 mm)较常氧对照组（128.00 g;377.50 ± 20.75 g;260.50 ± 9.35 g;15.78 ± 2.38 mm）和配对组（119.40 g;375.86 ± 11.30 g;262.29 ± 7.90 g;15.71 ± 2.82 mm）均显著下降,配对组较常氧对照组无显著性差异;4周干预后,与常氧对照组相比,低氧组大鼠腓肠肌中与低氧相关的HIF1α显著增加(1.42 ± 0.19, P<0.05),Akt和p-Akt/Akt显著降低 (1.44 ± 0.13; 0.47 ± 0.08, P<0.05),配对组上述3种指标相对表达量均无显著性差异;在蛋白质合成方面,低氧组mTOR较常氧对照组显著下降(0.63 ± 0.18, P<0.05),配对组较常氧对照组差异不明显;低氧组腓肠肌中,4EBP1(1.14 ± 0.14)和p70S6K1(1.14 ± 0.11)较配对组显著下降(P<0.05)。在蛋白质分解方面,低氧组p-FoxO1和p-FoxO1/FoxO1比值较常氧对照组显著下降(0.71 ± 0.15; 0.78 ± 0.14, P<0.05);低氧组大鼠腓肠肌中,Atrogin1、MuRF1、Beclin1、LC3Ⅰ及LC3Ⅱ/Ⅰ比值均高于常氧对照组(1.35 ± 0.12; 1.30 ± 0.22; 1.17 ± 0.11; 1.03 ± 0.11; 1.35 ± 0.13, P<0.05);配对组与常氧对照组间无明显差异。低氧环境下骨骼肌中蛋白质合成相关基因表达减少,蛋白质分解相关基因表达增加,造成骨骼肌萎缩,体重下降,此变化与摄食量减少无关。     

低氧影响蛋白质合成和分解的平衡诱导骨骼肌萎缩

暴露在低氧环境下,可能会引起胃肠功能障碍和摄食量下降,打破骨骼肌蛋白质合成和分解平衡,造成骨骼肌萎缩。为探讨低氧环境下骨骼肌的萎缩是低氧环境引起的还是低氧诱发的摄食量减少所致,本研究检测大鼠腓肠肌中低氧时蛋白质合成与分解相关基因的蛋白质表达。将21只雄性SD大鼠,随机分为3组：常氧对照组、低氧组（氧浓度为12.4%,模拟海拔4 000 m高度）和配对组（大鼠的摄食量与低氧组前1 d的摄食量相同）,每组7只,每天记录大鼠体重和摄食量。4周后,HE染色法观察腓肠肌肌纤维形态,Western印迹测试相关蛋白质水平。低氧组和配对组摄食量在低氧干预初期,较常氧对照组有显著性下降(P<0.05),干预后期差异不明显;干预期间,低氧组大鼠体重平均增加量(102.10 g)、体重(341.20 ± 16.75 g)、肌肉总量（226.83 ± 8.33 g）和腓肠肌肌纤维横截面积(12.67 ± 1.83 mm)较常氧对照组（128.00 g;377.50 ± 20.75 g;260.50 ± 9.35 g;15.78 ± 2.38 mm）和配对组（119.40 g;375.86 ± 11.30 g;262.29 ± 7.90 g;15.71 ± 2.82 mm）均显著下降,配对组较常氧对照组无显著性差异;4周干预后,与常氧对照组相比,低氧组大鼠腓肠肌中与低氧相关的HIF1α显著增加(1.42 ± 0.19, P<0.05),Akt和p-Akt/Akt显著降低 (1.44 ± 0.13; 0.47 ± 0.08, P<0.05),配对组上述3种指标相对表达量均无显著性差异;在蛋白质合成方面,低氧组mTOR较常氧对照组显著下降(0.63 ± 0.18, P<0.05),配对组较常氧对照组差异不明显;低氧组腓肠肌中,4EBP1(1.14 ± 0.14)和p70S6K1(1.14 ± 0.11)较配对组显著下降(P<0.05)。在蛋白质分解方面,低氧组p-FoxO1和p-FoxO1/FoxO1比值较常氧对照组显著下降(0.71 ± 0.15; 0.78 ± 0.14, P<0.05);低氧组大鼠腓肠肌中,Atrogin1、MuRF1、Beclin1、LC3Ⅰ及LC3Ⅱ/Ⅰ比值均高于常氧对照组(1.35 ± 0.12; 1.30 ± 0.22; 1.17 ± 0.11; 1.03 ± 0.11; 1.35 ± 0.13, P<0.05);配对组与常氧对照组间无明显差异。低氧环境下骨骼肌中蛋白质合成相关基因表达减少,蛋白质分解相关基因表达增加,造成骨骼肌萎缩,体重下降,此变化与摄食量减少无关。     

低氧诱导因子-1α在低氧促成肌细胞增殖中的作用

目的:探讨低氧对大鼠骨骼肌成肌细胞(SkMs)增殖的影响及低氧诱导因子(HIF-1α)在低氧促成肌细胞增殖中的相关机制。方法:采用流式细胞仪观察了3、10%O2对SkMs细胞数量和增殖指数的影响;用RT-PCR方法检测了HIF-1αmRNA的表达,用Western blot方法检测了SkMs胞浆、胞核及总HIF-1α蛋白的水平。结果:低氧组较常氧组细胞数量和增殖指数增加(P0.05);HIF-1αmRNA、总蛋白水平在常氧组和低氧组中没有明显差异,常氧下胞浆中HIF-1α蛋白水平高于胞核内,低氧下HIF-1α蛋白水平在胞核内高于胞浆。结论:低氧能够促进SkMs增殖,HIF-1α可能是通过氧浓度调控的核转位的方式参与了低氧促SkMs的增殖。     

mTOR信号转导在肌肉抗阻训练中的作用

虽然抗阻训练在康复手段和日常运动训练中广泛应用,但其调节生长发育和萎缩状态下肌肉再生的信号转导通路迄今仍未阐明,近期有证据表明哺乳动物雷帕霉素靶蛋白(mTOR)通路在此方面具有一定作用.本文从mTOR介导的抗阻训练生理效应出发,综述了抗阻训练中mTOR信号转导通路在调节肌肉体积方面的重要作用.     

抗阻训练对增龄大鼠骨骼肌线粒体功能的影响*

目的: 从线粒体动力学的角度,探讨抗阻运动对增龄大鼠骨骼肌线粒体功能的影响。方法: 40只雄性SD大鼠随机分为4组:2月龄安静对照组(C1组)、2月龄抗阻运动训练组(R1组)、6月龄安静对照组(C2组)、6月龄抗阻运动训练组(R2组),每组10只。C1、C2组正常喂养,R1、R2组大鼠进行跑台坡度为35°,速度为15 m/min的抗阻运动,一次跑动15 s,间歇30 s,4次为一组,组间间歇3 min,3组为一次循环,一天为2个循环,循环间歇10 min,每周6 d,共8周。采用Western blot法测定各组大鼠股四头肌线粒体融合蛋白2(Mfn2)、GTP酶1(DRP1) 蛋白含量,使用流式细胞仪测定各组大鼠股四头肌线粒体膜电位(ΔΨm)、活性氧(ROS)和游离钙(Ca²⁺)水平。结果: ① 与C1组相比,R1组大鼠DRP1蛋白升高(P＜0.01)、Mfn2蛋白无显著变化,C2组大鼠DRP1、Mfn2蛋白均降低(P均＜0.01);与C2组相比,R2组大鼠DRP1、Mfn2蛋白均升高(P＜0.01,P＜0.05);与R1组相比,R2组DRP1、Mfn2蛋白均降低(P＜0.01,P＜0.05)。② 与C1组相比,R1组Ca²⁺含量降低(P＜0.01)、C2组Ca²⁺含量升高(P＜0.01);与C2组相比,R2组Ca²⁺含量降低(P＜0.01);与R1组相比,R2组Ca²⁺含量升高(P＜0.01)。③ 与C1组相比,R1组ROS含量有所上升,但无显著性差异,C2组ROS含量升高(P＜0.01);与C2组相比,R2组ROS含量降低(P＜0.01);与R1组相比,R2组ROS含量升高(P＜0.01)。④ 与C1组相比,C2组ΔΨm降低(P＜0.01);与C2组相比,R2组ΔΨm升高(P＜0.01);与R1组相比,R2组ΔΨm有所降低,但无统计学差异。结论: 大鼠增龄过程中股四头肌线粒体出现Ca²⁺堆积、活性氧增多、线粒体膜电位下降、融合蛋白减少等现象,抗阻训练可有效改善这些变化。     

低氧后处理诱导的低氧诱导因子-1α表达上调减轻H9c2心肌细胞低氧/复氧损伤北大核心CSCD

本文旨在探讨低氧后处理(hypoxic postconditioning)对低氧/复氧(hypoxia/reoxygenation,H/R)所致的心肌细胞损伤以及低氧诱导因子-1α(hypoxia inducible factor-1α,HIF-1α)表达的影响,并分析二者之间可能的关系。利用H9c2心肌细胞株建立低氧/复氧和低氧后处理模型,通过测定细胞存活率、细胞培养液中乳酸脱氢酶(lactate dehydrogenase,LDH)的活性及caspase-3活性来观察低氧/复氧造成的H9c2细胞的损伤,用Westernblot检测H9c2细胞内HIF-1α的蛋白水平,用real-timePCR检测细胞内HIF-1α的mRNA水平。结果显示,低氧后处理提高了低氧/复氧H9c2细胞的存活率,降低了LDH及caspase-3活性。同时,低氧后处理增加了H9c2细胞内HIF-1α的蛋白水平。预先利用HIF-1α脯氨酸羟化酶抑制剂DMOG上调HIF-1α的蛋白水平后,由低氧/复氧导致的H9c2细胞的损伤明显减轻,其效应与低氧后处理完全一致。对H9c2细胞内HIF-1α蛋白水平与细胞存活率进行相关性分析,结果显示二者呈显著正相关(r=0.743,P<0.01);而运用siRNA方法抑制细胞内HIF-1α基因表达后,显著削弱了低氧后处理减轻低氧/复氧细胞损伤的效应。以上结果提示,HIF-1α表达上调是低氧后处理减轻细胞低氧/复氧损伤的机制之一。     

低氧经mTOR/4E-BP1和FoxO1/Atrogin-1通路影响骨骼肌蛋白质积累

低氧暴露对骨骼肌蛋白质合成/分解的影响受到广泛关注,但该过程中相关调控通路的研究仍十分有限。本研究拟通过蛋白质相对积累量来研究合成和分解通路的变化。将骨骼肌细胞置于低氧环境中培养,分别在0 h、6 h、12 h和24 h收集细胞,并进行检测。免疫荧光观察肌球蛋白(myosin),翻译表面感应检测蛋白质合成,Western印迹法测试蛋白质合成相关基因(ERK1/2、p-ERK1/2、mTOR、p-mTOR、4E-BP1、p-4E-BP1)、蛋白质分解相关基因(泛素、FoxO1、p-FoxO1、MuRF1和Atrogin-1)表达量。结果发现,随着低氧干预时间延长,肌纤维直径和骨骼肌细胞中蛋白质相对积累量随时间逐渐减小(P<0.01)。与0 h相比,6 h p-4E-BP1/4E-BP1和Atrogin-1的表达显著上调(P<0.05),p-mTOR表达显著高于0 h(P<0.01);6 h和24 h p-mTOR/mTOR的比值显著大于0 h(P<0.05),而p-FoxO1/FoxO1的比值随时间逐渐减小(P<0.01)。上述结果表明,低氧干预能够使骨骼肌细胞直径减少、骨骼肌细胞蛋白质积累减少,并且低氧打破骨骼肌细胞蛋白质合成和分解的平衡,可能是通过调节mTOR/4E-BP1通路活性和FoxO1/Atrogin-1通路的活性实现的。     

Lipid-induced Muscle Insulin Resistance Is Mediated by GGPPS via Modulation of the RhoA/Rho Kinase Signaling Pathway

Elevated circulating free fatty acid levels are important contributors to insulin resistance in the muscle and liver, but the underlying mechanisms require further elucidation. Here, we show that geranylgeranyl diphosphate synthase 1 (GGPPS), which is a branch point enzyme in the mevalonic acid pathway, promotes lipid-induced muscle insulin resistance through activation of the RhoA/Rho kinase signaling pathway. We have found that metabolic perturbation would increase GGPPS expression in the skeletal muscles of db/db mice and high fat diet-fed mice. To address the metabolic effects of GGPPS activity in skeletal muscle, we generated mice with specific GGPPS deletions in their skeletal muscle tissue. Heterozygous knock-out of GGPPS in the skeletal muscle improved systemic insulin sensitivity and glucose homeostasis in mice fed both normal chow and high fat diets. These metabolic alterations were accompanied by activated PI3K/Akt signaling and enhanced glucose uptake in the skeletal muscle. Further investigation showed that the free fatty acid-stimulated GGPPS expression in the skeletal muscle was able to enhance the geranylgeranylation of RhoA, which further induced the inhibitory phosphorylation of IRS-1 (Ser-307) by increasing Rho kinase activity. These results implicate a crucial role of the GGPPS/RhoA/Rho kinase/IRS-1 pathway in skeletal muscle, in which it mediates lipid-induced systemic insulin resistance in obese mice. Therefore, skeletal muscle GGPPS may represent a potential pharmacological target for the prevention and treatment of obesity-related type 2 diabetes.     

CerS1-Derived C18:0 Ceramide in Skeletal Muscle Promotes Obesity-Induced Insulin Resistance

1. Download high-res image (204KB)
2. Download full-size image

     

FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma

Mesenchymal subtype of glioblastoma (GBM), identified as one of four clinically relevant molecular subtypes, has worst prognosis because of its close relation with the malignant biological properties induced by glial-mesenchymal transition (GMT). However, the molecular mechanism of GMT and its characterized molecule of GBM have not been studied. Forkhead box protein O1 (FOXO1) is at a convergence point of receptor tyrosine kinase signaling as one of the three core pathways implicated in GBM. Our previous study indicated that the inactivation of FOXO1 involved in the inhibition of GMT is an independent prognosis factor of GBM. In this study, we will further confirm the role of FOXO1 in GMT through cytological experiments to clarify how FOXO1 regulates GMT and its clinical significance. We established virus-infected FOXO1 overexpression and FOXO1 knockdown cells of U373 MG and U251 mediated by lentivirus, based on the effect of which FOXO1-correlated-GMT experiments were performed in vitro and in vivo. Our data suggested that FOXO1 played a crucial role in resistance to TMZ, BCNU, and CDDP; migration and invasion; and stem cell properties of glioma cells. FOXO1 may serve as a targeted biomarker for prediction of sensitivity to chemotherapy drugs, metastasis, and prognosis, which provides a new idea for mesenchymal GBM treatment.     

ROR1激活AKT/FOXO1信号介导非小细胞肺癌吉非替尼耐药

EGFR-TKI靶向治疗在非小细胞肺癌（non-small cell lung cancer, NSCLC）综合治疗中显示出重要作用;然而,耐药性却极大限制其临床治疗效果。受体酪氨酸激酶样孤儿受体（receptor tyrosine kinase-like orphan receptor 1, ROR1）是I型受体酪氨酸激酶家族中的成员,在肿瘤发生发展中发挥重要作用。本研究拟探讨ROR1介导非小细胞肺癌吉非替尼耐药的作用及机制。采用吉非替尼反复诱导非小细胞肺癌HCC827细胞,建立吉非替尼耐药细胞株HCC827/GR。应用荧光定量PCR和Western 印迹检测HCC827/GR内ROR1的表达。采用shRNA的方法体外检测ROR1敲除前后HCC827/GR对吉非替尼耐药的变化,采用体外检测ROR1过表达前后HCC827对吉非替尼耐药的变化。体内检测ROR1敲除前后HCC827/GR对吉非替尼耐药的变化。Western 印迹检测HCC827/GR内ROR1下游信号分子的活化。实时荧光定量PCR及Western 印迹结果显示,HCC827/GR耐药细胞中的ROR1 mRNA和蛋白质表达水平显著高于HCC827敏感细胞。体外干扰ROR1表达,可明显增强HCC827/GR耐药细胞对吉非替尼的敏感性 (IC50 15.3±3.69 vs. 4.2±1.38),增加吉非替尼诱导的细胞凋亡 (20.5±2.52 vs. 41.8±3.74)。体外过表达ROR1显著增强HCC827敏感细胞对吉非替尼的耐药性(IC50 0.8±0.52 vs. 2.2±0.87)。体内裸鼠移植瘤实验同样发现,干扰ROR1能增强HCC827/GR移植瘤对吉非替尼的敏感性。进一步研究发现,AKT/FOXO1信号在HCC827/GR耐药细胞中异常活化,而干扰ROR1能够抑制AKT的磷酸化,并上调FOXO1的表达。上述结果表明,ROR1参与非小细胞肺癌吉非替尼耐药,抑制ROR1能够逆转吉非替尼耐药,其机制与ROR1调控AKT/FOXO1信号有关。     

Identification of Small Ankyrin 1 as a Novel Sarco(endo)plasmic Reticulum Ca2+-ATPase 1 (SERCA1) Regulatory Protein in Skeletal Muscle

Small ankyrin 1 (sAnk1) is a 17-kDa transmembrane (TM) protein that binds to the cytoskeletal protein, obscurin, and stabilizes the network sarcoplasmic reticulum in skeletal muscle. We report that sAnk1 shares homology in its TM amino acid sequence with sarcolipin, a small protein inhibitor of the sarco(endo)plasmic reticulum Ca²⁺-ATPase (SERCA). Here we investigate whether sAnk1 and SERCA1 interact. Our results indicate that sAnk1 interacts specifically with SERCA1 in sarcoplasmic reticulum vesicles isolated from rabbit skeletal muscle, and in COS7 cells transfected to express these proteins. This interaction was demonstrated by co-immunoprecipitation and an anisotropy-based FRET method. Binding was reduced ∼2-fold by the replacement of all of the TM amino acids of sAnk1 with leucines by mutagenesis. This suggests that, like sarcolipin, sAnk1 interacts with SERCA1 at least in part via its TM domain. Binding of the cytoplasmic domain of sAnk1 to SERCA1 was also detected in vitro. ATPase activity assays show that co-expression of sAnk1 with SERCA1 leads to a reduction of the apparent Ca²⁺ affinity of SERCA1 but that the effect of sAnk1 is less than that of sarcolipin. The sAnk1 TM mutant has no effect on SERCA1 activity. Our results suggest that sAnk1 interacts with SERCA1 through its TM and cytoplasmic domains to regulate SERCA1 activity and modulate sequestration of Ca²⁺ in the sarcoplasmic reticulum lumen. The identification of sAnk1 as a novel regulator of SERCA1 has significant implications for muscle physiology and the development of therapeutic approaches to treat heart failure and muscular dystrophies linked to Ca²⁺ misregulation.